Inherited prion disease explained: more detail

How much of prion disease is genetic?

Between 10 and 15 percent of all prion disease is attributed to PRNP variants, with surveillance figures from different countries falling in the 5 to 15 percent band. Inheritance is autosomal dominant: one altered copy is sufficient, it usually comes from an affected parent, and a minority of cases arise from a de novo variant.

Four variants account for more than half of genetic prion disease: E200K, D178N, P102L and A117V. E200K is the most common, and the most common cause of genetic CJD worldwide.

What is known about penetrance?

Genetic prion diseases were once thought fully penetrant. That is no longer the position. A 2022 review from the Case Western Reserve prion group describes D178N and P102L as nearly completely penetrant, E200K as showing incomplete, age-associated penetrance with most carriers developing illness as they get older, and V180I and V210I as low penetrance variants at roughly 1 percent and 10 percent. For octapeptide repeat insertions, penetrance generally rises with repeat number; a one-repeat deletion is considered benign and a two-repeat deletion pathogenic with probably low penetrance.

The practical consequence is that a reported variant does not carry a single prognosis, and that penetrance estimates for the rarer variants rest on small numbers and on population database frequencies that are still being revised. An international study of 217 E200K carriers did not confirm earlier reports of anticipation, which that review attributes to ascertainment bias.

What does codon 129 do?

PRNP carries a common polymorphism at codon 129, methionine or valine. The 2022 review describes it as having the strongest influence across all prion diseases, and gives D178N as the most dramatic example: with 129M on the same allele as the variant the phenotype is usually fatal familial insomnia, and with 129V on that allele it is usually genetic CJD. The same variant produces two differently named diseases depending on a polymorphism that millions of people carry harmlessly.

Codon 129 also acts in acquired disease, where homozygosity raises risk; nearly all autopsy-confirmed variant CJD cases were methionine homozygotes.

For octapeptide repeat insertions the main determinant is repeat number: fewer than eight repeats tends towards a CJD-like picture, eight or more towards Gerstmann-Straussler-Scheinker syndrome.

How do the inherited forms present?

Onset is generally younger than in sporadic CJD, and duration is often longer, with some forms running closer to two years than to the several months typical of sporadic disease. Fatal familial insomnia is marked by disturbed sleep, autonomic features and progressive cognitive change; Gerstmann-Straussler-Scheinker syndrome often opens with ataxia and takes a slower course; genetic CJD can be clinically indistinguishable from the sporadic form. Within a single family, age at onset and the leading symptom can differ considerably, which makes individual prediction from a pedigree unreliable.

Because of that overlap, a family history is not required for a prion disease diagnosis, and its absence does not exclude a genetic cause. Surveillance centres sequence PRNP in suspected cases for that reason.

How do diagnostic tests behave in genetic cases?

CSF real-time quaking-induced conversion assays have become the mainstay of antemortem diagnosis, and their performance is not uniform across variants. A 2026 Annals of Neurology study from the Canadian national reference laboratory tested 116 diagnostic CSF samples, 61 sporadic CJD submitted between 2014 and 2024, 50 cases the paper groups as inherited prion disease, and 5 cases of variably protease-sensitive prionopathy, comparing substrates.

The modified assay using a deer mouse recombinant prion protein substrate reached 96.6 percent sensitivity across the whole set, against 87.1 percent for the standard hamster substrate and 72.4 percent for the widely used IQ-CSF assay. The gain was concentrated in the inherited cases. For fatal familial insomnia with D178N, the standard substrate detected 4 of 13 and the modified substrate 12 of 13; the paper notes that D178N associated with fatal familial insomnia is particularly refractory to testing by IQ-RT-QuIC. For Gerstmann-Straussler-Scheinker syndrome, the standard substrate detected 9 of 12 and the modified substrate all 12. E200K, V210I, octapeptide repeat insertions and D178N presenting as genetic CJD were positive with both substrates. One V180I case was missed by both of the substrates compared and detected only by the IQ assay.

The counselling point is that a negative CSF seeding assay in a family with fatal familial insomnia or Gerstmann-Straussler-Scheinker syndrome carries less weight than the same result in suspected sporadic CJD, and the result depends on which assay was used. Which assays a given national laboratory runs is worth confirming locally.

What is being questioned about transmission risk?

The figure quoted to families is a one in two chance for each child. A 2025 European Journal of Neurology study from Bioaraba and CIC bioGUNE analysed 24 pedigrees, 65 nuclear families and 151 offspring and reported 67.1 percent transmission for D178N, with a 95 percent confidence interval of 56.3 to 77.9, and 70.5 percent for E200K, with an interval of 60.4 to 80.6. The authors propose meiotic drive as the most plausible explanation and argue for variant-specific and sex-specific figures in counselling, and for reconsidering some preimplantation testing strategies.

The design is retrospective, 18 percent of genotypes were inferred rather than tested, and the sample is weighted towards Basque families, so the result stands as a signal to be replicated rather than a replacement for the figure in current guidance. Both numbers are worth knowing when a family asks why they have seen different percentages. PRNP variants explained goes variant by variant.

Where is PRNP testing done?

Testing is usually arranged through a clinical genetics service or a national prion centre rather than ordered directly. In the United States, the National Prion Disease Pathology Surveillance Center accepts two 5 mL EDTA tubes at room temperature, states a 15 business day turnaround from receipt, requires a genetic consent form and a completed social and family history section, and does not test patients under 18. In Australia, the national CJD registry has PRNP testing run by the Neurogenetics Unit of PathWest Laboratory Medicine in Nedlands on peripheral blood or unfixed autopsy brain tissue, states that testing is entirely voluntary, and recommends consultation with a genetic service. That registry page also recommends storing DNA from every suspected case, so that relatives can consider testing later; raising this during the illness rather than afterwards gives a family the option.

Commercial laboratories in several countries list PRNP single gene sequencing, or dementia panels that include PRNP. Sequencing of the coding region does not reliably detect octapeptide repeat insertions, so where a repeat insertion is suspected clinically the laboratory has to be asked for a method that can find it.